Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 2/2015

01-06-2015 | The Global Epidemic (SH Vermund, Section Editor)

Innovative Strategies for Scale up of Effective Combination HIV Prevention Interventions in Sub-Saharan Africa

Authors: Kwame Shanaube, Peter Bock

Published in: Current HIV/AIDS Reports | Issue 2/2015

Login to get access

Abstract

For the last three decades, sub-Saharan Africa has been the epicentre of the HIV epidemic. Some key drivers of the epidemic are specific to this region and there is an urgent need to develop context-specific strategies to reduce HIV-related burden. Implementation frameworks should endeavour to combine structural, behavioural and biomedical interventions and the future of the HIV response involves embracing different approaches for different populations; it is not ‘one-size fits all approach’. Expanded use of community-based interventions will be key in expanding the role of antiretroviral treatment as prevention (TasP) in the region. For TasP to be effective, high antiretroviral therapy (ART) coverage rates need to be attained. Data from programmatic trials currently underway will provide crucial data to guide the future implementation of TasP.
Literature
1.
2.
Vermund SH, Fidler SJ, Ayles H, Beyers N, Hayes RJ. Can combination prevention strategies reduce HIV transmission in generalized epidemic settings in Africa? The HPTN 071 (PopART) study plan in South Africa and Zambia. J Acquir Immune Defic Syndr. 2013;63 Suppl 2:S221–7.CrossRefPubMedCentralPubMed
3.
Kurth AE, Celum C, Baeten JM, Vermund SH, Wasserheit JN. Combination HIV prevention: significance, challenges, and opportunities. Curr HIV/AIDS Rep. 2011;8(1):62–72.CrossRefPubMedCentralPubMed
4.
Joint United Nations Programme on HIV/AIDS. UNAIDS. FAST-TRACK: ending the AIDS epidemic by 2030. Geneva: Joint United Nations Programme on HIV/AIDS; 2014.
5.
United Nations. The millennium development goals report 2012. New York: United Nations; 2012.
6.•
Delva W, Abdool Karim Q. The HIV epidemic in Southern Africa - Is an AIDS-free generation possible? Curr HIV/AIDS Rep. 2014;11(2):99–108. There are persistent high HIV prevalence rates amongst women aged 15–24 in SSA.
7.
Gouws E, Cuchi P. Focusing the HIV response through estimating the major modes of HIV transmission: a multi-country analysis. Sex Transm Infect. 2012;88 Suppl 2:i76–85.CrossRefPubMedCentralPubMed
8.
UNAIDS. Global report on the AIDS epidemic 2013. Geneva: UNAIDS; 2013.
9.
Larmarange J, Wade AS, Diop AK, Diop O, Gueye K, Marra A, et al. Men who have sex with men (MSM) and factors associated with not using a condom at last sexual intercourse with a man and with a woman in Senegal. PLoS One. 2010;5(10):e13189.
10.
Beyrer C, Trapence G, Motimedi F, Umar E, Iipinge S, Dausab F, et al. Bisexual concurrency, bisexual partnerships, and HIV among Southern African men who have sex with men. Sex Transm Infect. 2010;86(4):323–7.CrossRefPubMed
11.•
Schwartlander B, Stover J, Hallett T, Atun R, Avila C, Gouws E, et al. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet. 2011;377(9782):2031–41. Global health funders need to be strategic in targeting populations in high burden regions based on disease epidemiology. A human rights approach that maximises community mobilisation may be effective.
12.
Ross DA. Behavioural interventions to reduce HIV risk: what works? AIDS (London, England). 2010;24 Suppl 4:S4–14.CrossRef
13.
Cremin I, Nyamukapa C, Sherr L, Hallett TB, Chawira G, Cauchemez S, et al. Patterns of self-reported behaviour change associated with receiving voluntary counselling and testing in a longitudinal study from Manicaland, Zimbabwe. AIDS Behav. 2010;14(3):708–15.CrossRefPubMedCentralPubMed
14.
Bello G, Simwaka B, Ndhlovu T, Salaniponi F, Hallett TB. Evidence for changes in behaviour leading to reductions in HIV prevalence in urban Malawi. Sex Transm Infect. 2011;87(4):296–300.CrossRefPubMedCentralPubMed
15.
16.
Hayes R, Watson-Jones D, Celum C, van de Wijgert J, Wasserheit J. Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning? AIDS (London, England). 2010;24 Suppl 4:S15–26.CrossRef
17.
Auvert B, Males S, Puren A, Taljaard D, Carael M, Williams B. Can highly active antiretroviral therapy reduce the spread of HIV?: A study in a township of South Africa. J Acquir Immune Defic Syndr. 2004;36(1):613–21.CrossRefPubMed
18.
Lewis DA. HIV/sexually transmitted infection epidemiology, management and control in the IUSTI Africa region: focus on sub-Saharan Africa. Sex Transm Infect. 2011;87 Suppl 2:ii10–3.PubMedCentralPubMed
19.
Alam N, Chamot E, Vermund SH, Streatfield K, Kristensen S. Partner notification for sexually transmitted infections in developing countries: a systematic review. BMC Public Health. 2010;10:19.CrossRefPubMedCentralPubMed
20.
Fidler S, Bock P. Prophylactic antiretroviral HIV therapy prevents infection in heterosexual men and women. Evid Based Med. 2013;18(5):184–5.
21.
Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342(13):921–9.CrossRefPubMed
22.•
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. New Engl J Med. 2011;365(6):493–505. HPTN 052, a RCT, showed a 96 % reduction in HIV transmission amongst discordant couples but evidence for effectiveness of this approach in reducing HIV incidence from community trials is limited.
23.•
Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science (New York, NY). 2013;339(6122):966–71. Increased ART coverage in a programmatic setting is associated with decreased HIV incidence.
24.
Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48–57.CrossRefPubMed
25.
Cori A, Ayles H, Beyers N, Schaap A, Floyd S, Sabapathy K, et al. HPTN 071 (PopART): a cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: mathematical model. PLoS One. 2014;9(1):e84511.CrossRefPubMedCentralPubMed
26.
27.
Gulick RM. Case-based discussion held in collaboration with the International Antiviral Society-USA (ISA-USA) When to start ART and what to start. Glasgow: HIV Drug Therapy Glasgow meeting; 2014.
28.
Lockman S, Sax P. Treatment-for-prevention: clinical considerations. Curr Opin HIV AIDS. 2012;7(2):131–9.CrossRefPubMed
29.
National Institutes of Health. Early antiretroviral treatment and/or early isoniazid prophylaxis against tuberculosis in HIV-infected adults (ANRS 12136 TEMPRANO). Washington: National Institute for Health; 2007.
30.
Babiker AG, Emery S, Fätkenheuer G, Gordin FM, Grund B, Lundgren JD, et al. Considerations in the rationale, design and methods of the Strategic Timing of Anti-Retroviral Treatment (START) study. Clinical Trials. 2013;10(1 suppl):S5–S36.
31.
Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373(9672):1352–63.CrossRefPubMed
32.
Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815–26.CrossRefPubMedCentralPubMed
33.•
Geffen N RM, Venter F& Low M. One size doesnt fit all: Tailoring adult antiretriviral treatment South African Journal of HIV Medicine. 2014 15(3). A more individualistic approach to ART provision regardless of CD4 count and WHO stage may be more effective than current standardised guidelines.
34.
Turashvili M, Becher H, Kerschberger B, Jouquet G, Browne M, Haye JL, et al. Decentralisation of HIV/TB care in Shiselweni region of Swaziland: making a difference. Vienna Evaluation Unit. 2014. http://​hdl.​handle.​net/​10144/​325599. Accessed 9 Jan 2014.
35.
Hayes R, Ayles H, Beyers N, Sabapathy K, Floyd S, Shanaube K, et al. HPTN 071 (PopART): rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment - a study protocol for a cluster randomised trial. Trials. 2014;15(1):57.CrossRefPubMedCentralPubMed
36.
37.
38.
Iwuji C, Orne-Gliemann J, Tanser F, Boyer S, Lessells R, Lert F, et al. Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence: the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa: study protocol for a cluster randomised controlled trial. Trials. 2013;14(1):230.
39.
40.
41.
Labhardt ND, Motlomelo M, Cerutti B, Pfeiffer K, Kamele M, Hobbins MA, et al. Home-based versus mobile clinic HIV testing and counseling in rural Lesotho: a cluster-randomized trial. PLoS Med. 2014;11(12):e1001768.CrossRefPubMedCentralPubMed
42.
Sweat M, Morin S, Celentano D, Mulawa M, Singh B, Mbwambo J, et al. Community-based intervention to increase HIV testing and case detection in people aged 16-32 years in Tanzania, Zimbabwe, and Thailand (NIMH Project Accept, HPTN 043): a randomised study. Lancet Infect Dis. 2011;11(7):525–32.CrossRefPubMedCentralPubMed
43.
Suthar AB, Ford N, Bachanas PJ, Wong VJ, Rajan JS, Saltzman AK, et al. Towards universal voluntary HIV testing and counselling: a systematic review and meta-analysis of community-based approaches. PLoS Med. 2013;10(8):e1001496.CrossRefPubMedCentralPubMed
44.
Napierala Mavedzenge S, Baggaley R, Corbett EL. A review of self-testing for HIV: research and policy priorities in a new era of HIV prevention. Clin Infect Dis. 2013;57(1):126–38.CrossRefPubMedCentralPubMed
45.
Choko AT, Desmond N, Webb EL, Chavula K, Napierala-Mavedzenge S, Gaydos CA, et al. The uptake and accuracy of oral kits for HIV self-testing in high HIV prevalence setting: a cross-sectional feasibility study in Blantyre. Malawi. PLoS Med. 2011;8(10):e1001102.CrossRefPubMedCentralPubMed
46.
Cornell M, Grimsrud A, Fairall L, Fox MP, van Cutsem G, Giddy J, et al. Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa. AIDS (London, England). 2010;24(14):2263–70.CrossRef
47.
Bemelmans M, Baert S, Goemaere E, Wilkinson L, Vandendyck M, van Cutsem G, et al. Community-supported models of care for people on HIV treatment in sub-Saharan Africa. Trop Med Int Health. 2014;19(8):968–77.CrossRefPubMed
48.
49.
Jones A, Cremin I, Abdullah F, Idoko J, Cherutich P, Kilonzo N, et al. Transformation of HIV from pandemic to low-endemic levels: a public health approach to combination prevention. Lancet. 2014;384(9939):272–9.CrossRefPubMed
Metadata
Title
Innovative Strategies for Scale up of Effective Combination HIV Prevention Interventions in Sub-Saharan Africa
Authors
Kwame Shanaube
Peter Bock
Publication date
01-06-2015
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 2/2015
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-015-0262-z

Other articles of this Issue 2/2015

Current HIV/AIDS Reports 2/2015 Go to the issue

The Global Epidemic (SH Vermund, Section Editor)

Quality of Care and Service Expansion for HIV Care and Treatment

The Global Epidemic (SH Vermund, Section Editor)

Implementation Research for the Prevention of Mother-to-Child HIV Transmission in Sub-Saharan Africa: Existing Evidence, Current Gaps, and New Opportunities

The Global Epidemic (SH Vermund, Section Editor)

Southern Africa: the Highest Priority Region for HIV Prevention and Care Interventions

Central Nervous System and Cognition (SS Spudich, Section Editor)

Neuropathology of HAND With Suppressive Antiretroviral Therapy: Encephalitis and Neurodegeneration Reconsidered

The Global Epidemic (SH Vermund, Section Editor)

A Political and Social History of HIV in South Africa

The Global Epidemic (SH Vermund, Section Editor)

Inflammation and HIV Transmission in Sub-Saharan Africa
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits